Suzanne M. Crumley
Research Subjects
Suzanne M. Crumley has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Cyrus Vaziri
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA
26 shared publications - Di Wu
Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA
26 shared publications - Emily M. Rabjohns
Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina
26 shared publications - Hannah N. Lee
Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina
26 shared publications - Jessica L. Bowser
Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina
26 shared publications - Luan H. Phan
Department of Internal Medicine, University of Texas McGovern Medical School, Houston, Texas
26 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Clinical features and PTEN expression in relation to CD73 staining patterns across individual EECMSS.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Clinical features and PTEN expression in relation to CD73 staining patterns across individual EECMSS.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S8 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
PD-L1 does not associate with increased CD8+ immune cell infiltration in cancer cell CD73-high or -low G2 EECMSS.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S8 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
PD-L1 does not associate with increased CD8+ immune cell infiltration in cancer cell CD73-high or -low G2 EECMSS.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Strong stromal cell CD73 expression is not associated with clinical features or patient outcomes in EECMSS.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Strong stromal cell CD73 expression is not associated with clinical features or patient outcomes in EECMSS.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
PD-L1 does not associate with increased CD3+ immune cell infiltration in G2 EECMSS with high to moderate cancer cell CD73.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
PD-L1 does not associate with increased CD3+ immune cell infiltration in G2 EECMSS with high to moderate cancer cell CD73.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Clinicopathological features of immunohistochemistry cohort of MSS/ MMR-proficient grade 2 endometrioid endometrial carcinomas.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Clinicopathological features of immunohistochemistry cohort of MSS/ MMR-proficient grade 2 endometrioid endometrial carcinomas.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Immunosuppressive genes with ≥ 3 positive correlations with proinflammatory genes of the cytokine-cytokine receptor interaction group in NT5E low tumors.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Immunosuppressive genes with ≥ 3 positive correlations with proinflammatory genes of the cytokine-cytokine receptor interaction group in NT5E low tumors.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Cytokine-cytokine receptor interaction group genes upregulated in NT5E low G2 EECMSS.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Cytokine-cytokine receptor interaction group genes upregulated in NT5E low G2 EECMSS.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Neutrophil activation pathways genes upregulated in NT5E-/- HEC-1-A cells.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
Neutrophil activation pathways genes upregulated in NT5E-/- HEC-1-A cells.
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
CD73 is an emerging immunotherapy target that is overexpressed in many tumors and generates an adenosine-rich microenvironment to suppress antitumor immunity. In low-grade endometrial carcinoma, CD73 expression varies, and its impact on tumor immunobiology is unknown. Using two microsatellite-stable, grade 2 endometrioid endometrial carcinoma cohorts, in vitro NT5E (CD73) knockout/knockdown, and single-cell and spatial analyses, we show that cancer cell CD73 loss promotes a dual inflammatory and immunosuppressive microenvironment. Cancer cell CD73 loss was associated with increased lymphovascular space invasion and worse recurrence-free and overall survival, whereas stromal CD73 expression did not correlate with outcomes. CD73 downregulation induced pro-inflammatory gene expression, which strongly correlated with upregulation of immunosuppressive genes, including CD274 (PD-L1), suggesting a compensatory mechanism limiting antitumor immunity. Tumors with low cancer cell CD73 exhibited higher PD-L1 expression that correlated with increased CD3+ T-cell infiltration, reflecting an immune-engaged but checkpoint-restrained microenvironment. Single-cell analyses demonstrated that NT5E+ nonimmune cells in immune-responsive clusters were three times less likely to express CD274. In clinically relevant low-grade endometrial carcinoma models, functional studies confirmed that CD73 loss promoted both pro-inflammatory and immunosuppressive programs. These results reveal a context-specific role for CD73 in shaping the immune landscape of low-grade endometrial carcinoma that is distinct from its function in other solid tumors. Significance:Unlike most cancers, in which CD73 drives immunosuppression via overexpression, we show that cancer cell CD73 loss promotes an inflammatory yet compensatory immunosuppressive microenvironment in low-grade endometrial carcinoma, revealing a context-specific role. CD73 loss in endometrial carcinoma therefore may be as immunologically significant as its overexpression in other cancers.
- 5 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cancer Cell CD73 Loss Promotes a Dual Inflammatory and Immunosuppressive Microenvironment in Endometrial Carcinoma
CD73 is an emerging immunotherapy target that is overexpressed in many tumors and generates an adenosine-rich microenvironment to suppress antitumor immunity. In low-grade endometrial carcinoma, CD73 expression varies, and its impact on tumor immunobiology is unknown. Using two microsatellite-stable, grade 2 endometrioid endometrial carcinoma cohorts, in vitro NT5E (CD73) knockout/knockdown, and single-cell and spatial analyses, we show that cancer cell CD73 loss promotes a dual inflammatory and immunosuppressive microenvironment. Cancer cell CD73 loss was associated with increased lymphovascular space invasion and worse recurrence-free and overall survival, whereas stromal CD73 expression did not correlate with outcomes. CD73 downregulation induced pro-inflammatory gene expression, which strongly correlated with upregulation of immunosuppressive genes, including CD274 (PD-L1), suggesting a compensatory mechanism limiting antitumor immunity. Tumors with low cancer cell CD73 exhibited higher PD-L1 expression that correlated with increased CD3+ T-cell infiltration, reflecting an immune-engaged but checkpoint-restrained microenvironment. Single-cell analyses demonstrated that NT5E+ nonimmune cells in immune-responsive clusters were three times less likely to express CD274. In clinically relevant low-grade endometrial carcinoma models, functional studies confirmed that CD73 loss promoted both pro-inflammatory and immunosuppressive programs. These results reveal a context-specific role for CD73 in shaping the immune landscape of low-grade endometrial carcinoma that is distinct from its function in other solid tumors. Significance:Unlike most cancers, in which CD73 drives immunosuppression via overexpression, we show that cancer cell CD73 loss promotes an inflammatory yet compensatory immunosuppressive microenvironment in low-grade endometrial carcinoma, revealing a context-specific role. CD73 loss in endometrial carcinoma therefore may be as immunologically significant as its overexpression in other cancers.